Clinical Trial Update: Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating osimertinib with or without ramucirumab in locally advanced or metastatic non-small cell lung cancer with EGFR mutation; the study is c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Cyramza (ramucirumab)
• TAGRISSO (osimertinib)

Snippet

Sponsor: Xiuning Le | Conditions: Non Small Cell Lung Cancer, EGFR Gene Mutation | Phase 2 | Status: ACTIVE_NOT_RECRUITING